Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer

Durvalumab after concurrent chemoradiation has significantly improved survival in stage III non-small cell lung cancer (NSCLC). However, there is limited data evaluating the utilization and challenges to deliver durvalumab consolidation in the real world. We assessed the use of consolidative durvalu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Radiother Oncol
Egile Nagusiak: Shaverdian, Narek, Offin, Michael D., Rimner, Andreas, Shepherd, Annemarie F., Wu, Abraham J., Rudin, Charles M., Hellmann, Matthew D., Chaft, Jamie E., Gomez, Daniel R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7523024/
https://ncbi.nlm.nih.gov/pubmed/31786421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2019.11.015
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak